These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14670643)

  • 21. Progestin type affects the increase of heparanase level and procoagulant activity mediated by the estrogen receptor.
    Treger S; Ackerman S; Kaplan V; Ghanem S; Nadir Y
    Hum Reprod; 2021 Jan; 36(1):61-69. PubMed ID: 33306105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation.
    Bastianelli C; Farris M; Rosato E; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1085-1098. PubMed ID: 30325245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of estrogens and progestogens on lipid metabolism.
    Oster P; Arab L; Kohlmeier M; Mordasini R; Schellenberg B; Schlierf G
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):773-5. PubMed ID: 7065057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD; Lawrenson RA
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease.
    Kelleher CC
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):392-5. PubMed ID: 2196811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The adverse effects of hormonal therapy.
    Bush TL
    Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progestin-only pills for contraception.
    Grimes DA; Lopez LM; O'Brien PA; Raymond EG
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007541. PubMed ID: 20091638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential.
    Ellis J
    Clin Ther; 1986; 8(6):607-18. PubMed ID: 3539347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
    Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
    Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection.
    Rosano GM; Vitale C; Silvestri A; Fini M
    Maturitas; 2003 Dec; 46 Suppl 1():S17-29. PubMed ID: 14670642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills.
    Sitruk-Ware R; Nath A
    Best Pract Res Clin Endocrinol Metab; 2013 Feb; 27(1):13-24. PubMed ID: 23384742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology of hormonal contraceptives-related venous thromboembolism.
    Hugon-Rodin J; Gompel A; Plu-Bureau G
    Eur J Endocrinol; 2014 Dec; 171(6):R221-30. PubMed ID: 25012200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.
    Gomes MP; Deitcher SR
    Arch Intern Med; 2004 Oct; 164(18):1965-76. PubMed ID: 15477430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
    Plu-Bureau G; Sabbagh E; Hugon-Rodin J
    Gynecol Obstet Fertil Senol; 2018 Dec; 46(12):823-833. PubMed ID: 30389542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.